EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data

Alexander Olkus, Aurelie Tomczak, Anne Katrin Berger, Conrad Rauber, Philip Puchas, Cyrill Wehling, Thomas Longerich, Arianeb Mehrabi, De-Hua Chang, Jakob Liermann, Sophia Schäfer, Jan Pfeiffenberger und 4 weitere

Targeted Oncology · 2024-03 · 19 (2) · 213-221

DOI: 10.1007/s11523-024-01044-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Targeted Oncology, online erschienen am 28.02.2024. Verfasst von Alexander Olkus und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Infectious Diseases and Intoxication, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Ger…. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Bile Duct Neoplasms, Antibodies, Monoclonal. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Krebshilfe, German Ministry of Research and Education, Universitätsklinikum Heidelberg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biliary Tract NeoplasmsBile Duct NeoplasmsAntibodies, MonoclonalHumansGemcitabineCisplatinRetrospective StudiesAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidine

Substanzen

GemcitabineCisplatindurvalumabDeoxycytidineAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Gastroenterology, Infectious Diseases and Intoxication, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
  • Liver Cancer Center Heidelberg, Heidelberg, Germany.
  • Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Department of Medical Oncology, Heidelberg University Hospital, Heidelberg, Germany.
  • National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.
  • Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.

ORCID-Profile: Michael T Dill

Förderung

  • Deutsche Krebshilfe
  • German Ministry of Research and Education
  • Universitätsklinikum Heidelberg

Zitieren

APA

Olkus, A., Tomczak, A., Berger, A. K., Rauber, C., Puchas, P., Wehling, C., Longerich, T., Mehrabi, A., Chang, D. H., Liermann, J., Schäfer, S., Pfeiffenberger, J., Jäger, D., Michl, P., Springfeld, C., & Dill, M. T. (2024). Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data. Targeted Oncology, 19(2), 213-221. https://doi.org/10.1007/s11523-024-01044-1

Vancouver

Olkus A, Tomczak A, Berger AK, Rauber C, Puchas P, Wehling C, et al. Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data. Targeted Oncology. 2024;19(2):213-221. doi:10.1007/s11523-024-01044-1

BibTeX
@article{Olkus2024,
  author = {Olkus, Alexander and Tomczak, Aurelie and Berger, Anne Katrin and Rauber, Conrad and Puchas, Philip and Wehling, Cyrill and Longerich, Thomas and Mehrabi, Arianeb and Chang, De-Hua and Liermann, Jakob and Schäfer, Sophia and Pfeiffenberger, Jan and Jäger, Dirk and Michl, Patrick and Springfeld, Christoph and Dill, Michael T},
  title = {Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data},
  journal = {Targeted Oncology},
  year = {2024},
  volume = {19},
  number = {2},
  pages = {213--221},
  doi = {10.1007/s11523-024-01044-1}
}
Kostenlos starten →